BRCA2 and ovarian carcinoma: These inhibitors have been described as a powerful therapy for patients with hereditary breast or ovarian cancer containing mutations in the BRCA-1 and BRCA-2 genes that are essential for repairing DNA lesions by the homologous recombination pathway [51, 52].